Inventor · disambiguated record
Langyong Mao
Also filed as: MAO LANGYONG
0 granted patents·8 pending applications·0 citations·filing 2020–2022
Technology areasC07K
Top patents by PatentIndex Score
8 records- 0160US2024400670A1Anti-il23 antibody fusion protein and uses thereofJIANGSU HENGRUI PHARMACEUTICALS CO LTD·Filed 2022·Application pending·0 cites
- 0258US2024301031A1Truncated taci polypeptide and fusion protein and use thereofJIANGSU HENGRUI PHARMACEUTICALS CO LTD·Filed 2022·Application pending·0 cites
- 0358US2024392020A1Antigen-binding moleculeJIANGSU HENGRUI PHARMACEUTICALS CO LTD·Filed 2022·Application pending·0 cites
- 0455US2024254245A1Antigen binding molecule specifically binding to rankl and ngf, and medical use thereofJIANGSU HENGRUI PHARMACEUTICALS CO LTD·Filed 2022·Application pending·0 cites
- 0554US2023055408A1Anti-cea antibody-exatecan analog conjugate and pharmaceutical use thereofJIANGSU HENGRUI MEDICINE CO·Filed 2020·Application pending·0 cites
- 0653US2023120270A1New polypeptide complexJIANGSU HENGRUI MEDICINE CO·Filed 2021·Application pending·0 cites
- 0751US2023013784A1Anti-cea antibody and application thereofJIANGSU HENGRUI MEDICINE CO·Filed 2020·Application pending·0 cites
- 0846US2022185875A1Bispecific antibody specifically bound to vegf and ang2JIANGSU HENGRUI MEDICINE CO·Filed 2020·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Langyong Mao files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →